Hardi Mundl

7PUBLICATIONS
51CO-AUTHORS
Artificial life and complex adaptive systemsMedical microbiology not elsewhere classifiedBiologically active moleculesMedical infection agents (incl. prions)Cancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|May 16, 2025
An External Control Arm for the Oral Factor XIa Inhibitor Asundexian Phase 2 Trial in Atrial Fibrillation (PACIFIC-AF) Using Electronic Health Records.

Tatsiana Vaitsiakhovich, Alexander Hartenstein, Stephen Privitera

|May 01, 2024
Hemorrhagic Transformation in Noncardioembolic Acute Ischemic Stroke: MRI Analysis From PACIFIC-STROKE.

Chih-Hao Chen, Ashkan Shoamanesh, Pablo Colorado

|Jan 04, 2024
Effect of the Factor XIa Inhibitor Asundexian According to Baseline Infarct Pattern and on MRI Covert Infarct Outcomes.

Eric E Smith, Ashkan Shoamanesh, Lizhen Xu

|Nov 11, 2023
Cerebral microbleeds and asundexian in non-cardioembolic ischemic stroke: Secondary analyses of the PACIFIC-STROKE randomized trial.

Pargol Balali, Robert G Hart, Eric E Smith

|Aug 28, 2022
A Multicenter, Phase 2, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Dose-Finding Trial of the Oral Factor XIa Inhibitor Asundexian to Prevent Adverse Cardiovascular Outcomes After Acute Myocardial Infarction.

Sunil V Rao, Bodo Kirsch, Deepak L Bhatt

|Nov 18, 2021
Rivaroxaban versus aspirin for prevention of covert brain infarcts in patients with embolic stroke of undetermined source: NAVIGATE ESUS MRI substudy.

Mukul Sharma, Eric E Smith, Lesly A Pearce

Pageof 2

Frequent Collaborators

5 joint publications

Ashkan Shoamanesh

3 joint publications

Eric E Smith

3 joint publications

Valeria Caso

3 joint publications

Robert G Hart